Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase.

Huggins IJ, Medina CA, Springer AD, van den Berg A, Jadhav S, Cui X, Dowdy SF.

Molecules. 2019 Sep 10;24(18). pii: E3287. doi: 10.3390/molecules24183287.

2.

Controlling CRISPR-Cas9 Gene Editing.

Dowdy SF.

N Engl J Med. 2019 Jul 18;381(3):289-290. doi: 10.1056/NEJMcibr1906886. No abstract available.

PMID:
31314976
3.

GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.

Springer AD, Dowdy SF.

Nucleic Acid Ther. 2018 Jun;28(3):109-118. doi: 10.1089/nat.2018.0736. Epub 2018 May 24. Review.

4.

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Dowdy SF, Levy M.

Nucleic Acid Ther. 2018 Jun;28(3):107-108. doi: 10.1089/nat.2018.29001.dow. Epub 2018 May 21. No abstract available.

PMID:
29782220
5.

Induction of RNAi Responses by Short Left-Handed Hairpin RNAi Triggers.

Hagopian JC, Hamil AS, van den Berg A, Meade BR, Eguchi A, Palm-Apergi C, Dowdy SF.

Nucleic Acid Ther. 2017 Oct;27(5):260-271. doi: 10.1089/nat.2017.0686. Epub 2017 Sep 21.

6.

Enhanced generation of iPSCs from older adult human cells by a synthetic five-factor self-replicative RNA.

Yoshioka N, Dowdy SF.

PLoS One. 2017 Jul 27;12(7):e0182018. doi: 10.1371/journal.pone.0182018. eCollection 2017.

7.

RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients.

Kolosenko I, Edsbäcker E, Björklund AC, Hamil AS, Goroshchuk O, Grandér D, Dowdy SF, Palm-Apergi C.

J Control Release. 2017 Sep 10;261:199-206. doi: 10.1016/j.jconrel.2017.07.002. Epub 2017 Jul 3.

PMID:
28684168
8.

Overcoming cellular barriers for RNA therapeutics.

Dowdy SF.

Nat Biotechnol. 2017 Mar;35(3):222-229. doi: 10.1038/nbt.3802. Epub 2017 Feb 27. Review.

PMID:
28244992
9.

Enhancing Endosomal Escape for Intracellular Delivery of Macromolecular Biologic Therapeutics.

Lönn P, Kacsinta AD, Cui XS, Hamil AS, Kaulich M, Gogoi K, Dowdy SF.

Sci Rep. 2016 Sep 8;6:32301. doi: 10.1038/srep32301.

10.

53BP1 and USP28 mediate p53 activation and G1 arrest after centrosome loss or extended mitotic duration.

Meitinger F, Anzola JV, Kaulich M, Richardson A, Stender JD, Benner C, Glass CK, Dowdy SF, Desai A, Shiau AK, Oegema K.

J Cell Biol. 2016 Jul 18;214(2):155-66. doi: 10.1083/jcb.201604081.

11.

Voices of biotech.

Amit I, Baker D, Barker R, Berger B, Bertozzi C, Bhatia S, Biffi A, Demichelis F, Doudna J, Dowdy SF, Endy D, Helmstaedter M, Junca H, June C, Kamb S, Khvorova A, Kim DH, Kim JS, Krishnan Y, Lakadamyali M, Lappalainen T, Lewin S, Liao J, Loman N, Lundberg E, Lynd L, Martin C, Mellman I, Miyawaki A, Mummery C, Nelson K, Paz J, Peralta-Yahya P, Picotti P, Polyak K, Prather K, Qin J, Quake S, Regev A, Rogers JA, Shetty R, Sommer M, Stevens M, Stolovitzky G, Takahashi M, Tang F, Teichmann S, Torres-Padilla ME, Tripathi L, Vemula P, Verdine G, Vollmer F, Wang J, Ying JY, Zhang F, Zhang T.

Nat Biotechnol. 2016 Mar;34(3):270-5. doi: 10.1038/nbt.3502. No abstract available.

PMID:
26963549
12.

Protein kinase Cζ exhibits constitutive phosphorylation and phosphatidylinositol-3,4,5-triphosphate-independent regulation.

Tobias IS, Kaulich M, Kim PK, Simon N, Jacinto E, Dowdy SF, King CC, Newton AC.

Biochem J. 2016 Feb 15;473(4):509-23. doi: 10.1042/BJ20151013. Epub 2015 Dec 3.

13.

Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.

Kacsinta AD, Dowdy SF.

Expert Opin Biol Ther. 2016;16(2):161-72. doi: 10.1517/14712598.2016.1110141. Epub 2015 Dec 2. Review.

PMID:
26630128
14.

Combining CRISPR/Cas9 and rAAV Templates for Efficient Gene Editing.

Kaulich M, Dowdy SF.

Nucleic Acid Ther. 2015 Dec;25(6):287-96. doi: 10.1089/nat.2015.0545. Epub 2015 Nov 5. Review.

15.

Synthesis and Conjugation of Small Interfering Ribonucleic Neutral SiRNNs.

Hamil AS, Dowdy SF.

Methods Mol Biol. 2016;1364:1-9. doi: 10.1007/978-1-4939-3112-5_1.

16.

Cationic PTD/CPP-mediated macromolecular delivery: charging into the cell.

Lönn P, Dowdy SF.

Expert Opin Drug Deliv. 2015;12(10):1627-36. doi: 10.1517/17425247.2015.1046431. Epub 2015 May 20. Review.

PMID:
25994800
17.

Efficient CRISPR-rAAV engineering of endogenous genes to study protein function by allele-specific RNAi.

Kaulich M, Lee YJ, Lönn P, Springer AD, Meade BR, Dowdy SF.

Nucleic Acids Res. 2015 Apr 20;43(7):e45. doi: 10.1093/nar/gku1403. Epub 2015 Jan 13.

18.

Cellular activity of siRNA oligonucleotides containing synthetic isomorphic nucleoside surrogates.

Shin D, Lönn P, Dowdy SF, Tor Y.

Chem Commun (Camb). 2015 Jan 31;51(9):1662-5. doi: 10.1039/c4cc08809c.

19.

Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications.

Meade BR, Gogoi K, Hamil AS, Palm-Apergi C, van den Berg A, Hagopian JC, Springer AD, Eguchi A, Kacsinta AD, Dowdy CF, Presente A, Lönn P, Kaulich M, Yoshioka N, Gros E, Cui XS, Dowdy SF.

Nat Biotechnol. 2014 Dec;32(12):1256-61. doi: 10.1038/nbt.3078. Epub 2014 Nov 17.

21.

Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade.

Wu X, Zhang W, Font-Burgada J, Palmer T, Hamil AS, Biswas SK, Poidinger M, Borcherding N, Xie Q, Ellies LG, Lytle NK, Wu LW, Fox RG, Yang J, Dowdy SF, Reya T, Karin M.

Proc Natl Acad Sci U S A. 2014 Sep 23;111(38):13870-5. doi: 10.1073/pnas.1414358111. Epub 2014 Sep 4.

22.

Cyclin D activates the Rb tumor suppressor by mono-phosphorylation.

Narasimha AM, Kaulich M, Shapiro GS, Choi YJ, Sicinski P, Dowdy SF.

Elife. 2014 Jun 4;3. doi: 10.7554/eLife.02872.

23.

Efficient generation of human iPSCs by a synthetic self-replicative RNA.

Yoshioka N, Gros E, Li HR, Kumar S, Deacon DC, Maron C, Muotri AR, Chi NC, Fu XD, Yu BD, Dowdy SF.

Cell Stem Cell. 2013 Aug 1;13(2):246-54. doi: 10.1016/j.stem.2013.06.001.

24.

Transdifferentiation of human fibroblasts into hepatocyte-like cells by defined transcriptional factors.

Kogiso T, Nagahara H, Otsuka M, Shiratori K, Dowdy SF.

Hepatol Int. 2013 Jul;7(3):937-44. doi: 10.1007/s12072-013-9432-5. Epub 2013 Mar 13.

PMID:
26201932
25.

DNA delivery into mammalian cells using bacteriophage λ displaying the TAT transduction domain.

Wadia J, Eguchi A, Dowdy SF.

Cold Spring Harb Protoc. 2013 Jan 1;2013(1). pii: pdb.prot072660. doi: 10.1101/pdb.prot072660.

PMID:
23282641
26.

PTD/CPP peptide-mediated delivery of siRNAs.

Presente A, Dowdy SF.

Curr Pharm Des. 2013;19(16):2943-7. Review.

PMID:
23140460
27.

A novel role for survivin in erythroblast enucleation.

Keerthivasan G, Liu H, Gump JM, Dowdy SF, Wickrema A, Crispino JD.

Haematologica. 2012 Oct;97(10):1471-9. doi: 10.3324/haematol.2011.061093. Epub 2012 Apr 4.

28.

Do cell-penetrating peptides actually "penetrate" cellular membranes?

Palm-Apergi C, Lönn P, Dowdy SF.

Mol Ther. 2012 Apr;20(4):695-7. doi: 10.1038/mt.2012.40. No abstract available.

29.

Protein transduction domain delivery of therapeutic macromolecules.

van den Berg A, Dowdy SF.

Curr Opin Biotechnol. 2011 Dec;22(6):888-93. doi: 10.1016/j.copbio.2011.03.008. Epub 2011 Apr 12. Review.

PMID:
21489777
30.

PTD-DRBD siRNA delivery.

Palm-Apergi C, Eguchi A, Dowdy SF.

Methods Mol Biol. 2011;683:339-47. doi: 10.1007/978-1-60761-919-2_24.

PMID:
21053141
31.
32.

C/EBP{delta} targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression.

Pawar SA, Sarkar TR, Balamurugan K, Sharan S, Wang J, Zhang Y, Dowdy SF, Huang AM, Sterneck E.

Proc Natl Acad Sci U S A. 2010 May 18;107(20):9210-5. doi: 10.1073/pnas.0913813107. Epub 2010 May 3.

33.

Efficient siRNA delivery by novel PTD-DRBD fusion proteins.

Eguchi A, Dowdy SF.

Cell Cycle. 2010 Feb 1;9(3):424-5. Epub 2010 Feb 18. No abstract available.

PMID:
20090414
34.
35.

Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma.

Michiue H, Eguchi A, Scadeng M, Dowdy SF.

Cancer Biol Ther. 2009 Dec;8(23):2306-13. Epub 2009 Dec 7.

PMID:
19901546
36.

Revised role of glycosaminoglycans in TAT protein transduction domain-mediated cellular transduction.

Gump JM, June RK, Dowdy SF.

J Biol Chem. 2010 Jan 8;285(2):1500-7. doi: 10.1074/jbc.M109.021964. Epub 2009 Oct 26.

37.

siRNA delivery using peptide transduction domains.

Eguchi A, Dowdy SF.

Trends Pharmacol Sci. 2009 Jul;30(7):341-5. doi: 10.1016/j.tips.2009.04.009. Epub 2009 Jun 21. Review.

PMID:
19545914
38.

Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein.

Eguchi A, Meade BR, Chang YC, Fredrickson CT, Willert K, Puri N, Dowdy SF.

Nat Biotechnol. 2009 Jun;27(6):567-71. doi: 10.1038/nbt.1541. Epub 2009 May 17.

39.

Whi5 regulation by site specific CDK-phosphorylation in Saccharomyces cerevisiae.

Wagner MV, Smolka MB, de Bruin RA, Zhou H, Wittenberg C, Dowdy SF.

PLoS One. 2009;4(1):e4300. doi: 10.1371/journal.pone.0004300. Epub 2009 Jan 28.

40.

A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.

Cerchietti LC, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn A, Dowdy SF, Melnick A.

Blood. 2009 Apr 9;113(15):3397-405. doi: 10.1182/blood-2008-07-168773. Epub 2008 Oct 16.

41.

Excision of selectable genes from transgenic goat cells by a protein transducible TAT-Cre recombinase.

Xu Y, Liu S, Yu G, Chen J, Chen J, Xu X, Wu Y, Zhang A, Dowdy SF, Cheng G.

Gene. 2008 Aug 1;419(1-2):70-4. doi: 10.1016/j.gene.2008.04.020. Epub 2008 May 13.

PMID:
18547746
42.

Sequential transcription factor targeting for diffuse large B-cell lymphomas.

Cerchietti LC, Polo JM, Da Silva GF, Farinha P, Shaknovich R, Gascoyne RD, Dowdy SF, Melnick A.

Cancer Res. 2008 May 1;68(9):3361-9. doi: 10.1158/0008-5472.CAN-07-5817.

43.

CDK inhibitors: cell cycle regulators and beyond.

Besson A, Dowdy SF, Roberts JM.

Dev Cell. 2008 Feb;14(2):159-69. doi: 10.1016/j.devcel.2008.01.013. Review.

44.

Protein transduction: generation of full-length transducible proteins using the TAT system.

Becker-Hapak M, Dowdy SF.

Curr Protoc Cell Biol. 2003 May;Chapter 20:Unit 20.2. doi: 10.1002/0471143030.cb2002s18.

PMID:
18228426
45.

Pathologic prion protein infects cells by lipid-raft dependent macropinocytosis.

Wadia JS, Schaller M, Williamson RA, Dowdy SF.

PLoS One. 2008;3(10):e3314. doi: 10.1371/journal.pone.0003314. Epub 2008 Oct 2.

46.

Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides.

Meade BR, Dowdy SF.

Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):530-6. Epub 2007 Oct 22. Review.

47.

TAT transduction: the molecular mechanism and therapeutic prospects.

Gump JM, Dowdy SF.

Trends Mol Med. 2007 Oct;13(10):443-8. Review.

PMID:
17913584
48.

Relocalized p27Kip1 tumor suppressor functions as a cytoplasmic metastatic oncogene in melanoma.

Denicourt C, Saenz CC, Datnow B, Cui XS, Dowdy SF.

Cancer Res. 2007 Oct 1;67(19):9238-43.

49.

Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides.

Meade BR, Dowdy SF.

Adv Drug Deliv Rev. 2007 Mar 30;59(2-3):134-40. Epub 2007 Mar 15. Review.

PMID:
17451840
50.

Cyclin D-Cdk4 is regulated by GATA-1 and required for megakaryocyte growth and polyploidization.

Muntean AG, Pang L, Poncz M, Dowdy SF, Blobel GA, Crispino JD.

Blood. 2007 Jun 15;109(12):5199-207. Epub 2007 Feb 22.

Supplemental Content

Loading ...
Support Center